| http://www.w3.org/ns/prov#value | - Given Baxter???s disastrous quality control record with respect to both approved human treatments (heparin) and preclinical studies (H5N1 and H3N2), shouldn???t the FDA and other regulatory agencies consider halting clinical trials with reagents that Baxter has handled until they have disclosed all information on the current incident?
|
